New research raises concerns about safety of higher-THC medicinal cannabis products in Australia

New Monash University research has found that more than half of all adverse events reported to Australia’s medicines regulator involving medicinal cannabis were linked to higher-THC products, with psychiatric disorders the most commonly reported adverse reactions.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup